Loading...
Please wait, while we are loading the content...
Similar Documents
Circulating matrix metalloproteinase-9 levels as a biomarker of disease.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Gerlach, Raquel Fernanda Tanus-Santos, José Eduardo |
| Copyright Year | 2005 |
| Abstract | To the Editor: Nikkola et al. (1) have recently addressed the prognostic value of serum levels of matrix metalloproteinase 9 (MMP-9), collagenase 1, and collagenase 3 in patients with advanced melanoma. Specifically, the serum levels of MMP-9 were determined by ELISA, Western blot, and gelatin zymog-raphy analysis. They have found that patients with high serum levels of MMP-9 had poorer overall survival than patients with lower serum MMP-9 levels, and high MMP-9 levels were found to be associated with metastasis, high alkaline phosphatase levels, and liver metastases. Therefore, they have concluded that serum MMP-9 could have clinical value in identifying patients at increased risk for melanoma progression1. There is evidence, however, indicating that their MMP-9 results in serum do not reliably reflect the circulating levels of MMP-9. Measurement of MMP-9 levels in serum has been reported as artificially high compared with the results obtained from plasma samples (2 – 4). In addition, there is no correlation between MMP-9 levels in serum and in plasma. In summary, preanalytic conditions and other methodologic issues are of major importance when assessing MMPs in clinical samples (5). Therefore, there is strong evidence indicating that serum samples should not be used to measure circulating MMP-9 levels as a diagnostic or as a prognostic marker of disease (6). References 1. Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metal-loproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. et al. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. In Response: We thank Prof. Tanus-Santos for his criticism on our article ''High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma'' published in Clinical Cancer Research on July 15, 2005 (1). We conclude that matrix metalloproteinase (MMP)-1, MMP-9, and MMP-13 have important roles at different phases of metastatic spread and that serum MMP-9, in particular, could be of clinical value when identifying patients at high risk for progression. Our original work was sent to Clinical Cancer Research in June 2003. At that time, there were only few studies about prognostic markers in metastatic melanoma and research activity has been increasing in recent years. We agree that there might be some … |
| Starting Page | 1967 |
| Ending Page | 1978 |
| Page Count | 12 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/11/24/8887.full.pdf |
| PubMed reference number | 16361580v1 |
| Volume Number | 11 |
| Issue Number | 24 |
| Part | 1 |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Alkaline Phosphatase Biological Markers COLLAGENASE Enzyme-Linked Immunosorbent Assay Hematological Disease MMP13 protein, human MMP9 gene Matrix Metalloproteinase 9 Matrix Metalloproteinases Metalloproteases Metastatic melanoma Neoplasm Metastasis Neoplasms Overall Survival Patients Research Activities Scientific Publication Specimen Collection Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization TIMP2 gene Tissue Inhibitor of Metalloproteinases Western Blot liver metastases |
| Content Type | Text |
| Resource Type | Article |
